UNSPSC 51151540: Distigmine bromide

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C22H32N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 750F36OP6J, chemically known as 3,3-(1,6-hexanediylbis((methylimino)carbonyl)oxy)bis(1-methylpyridinium) dibromide but more generally known as distigmine bromide, which bears US NIH Compound Identifier 27522. European Medicines Agency schedules Distigmine bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06323MIG.

UNSPSC 51151540 Distigmine bromide (Commodity) covers pharmaceutical products, but the recent state and local opportunities tagged under this code do not procure distigmine bromide specifically. Instead, Seminole County, Florida solicited naloxone and drug deactivation systems through IFB60459723LAS, and the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs. The code's nominal scope—a parasympathomimetic agent used in myasthenia gravis and other conditions—does not align with what state and local procurement offices are actually buying under this tag. Issuing bodies posting under this code include county health departments and state health agencies. The absence of solicitations for distigmine bromide itself suggests either low utilization of this specific pharmaceutical in state and local health systems or inconsistent UNSPSC coding in recent procurement records.

The recent opportunities span Florida and Texas. Seminole County's July 2026 IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with a two-year initial term and one-year renewal option. The Texas HHS RFI, posted April 2026, explored vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels, seeking responses on direct contracting experience, volume fulfillment strategies, and outcomes-based pricing flexibility. The mismatch between the code's pharmaceutical name and the actual procurement activity suggests this code may receive inconsistent application in state procurement systems, warranting verification of coding accuracy before pursuing opportunities tagged under it.